Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
midazolam; CP-690, 550+ midazolam · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence 1 | EXPERIMENTAL | - |
| Treatment Sequence 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| midazolam; CP-690,550 + midazolam | DRUG | Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID |
| CP-690,550 + midazolam; midazolam | DRUG | Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone |
Inclusion Criteria: * Healthy male and/or female (non-child bearing potential) subjects Exclusion Criteria: * Clinically significant infections within the past 3 months * History of previously untreated infection with Mycobacterium tuberculosis * Positive screening test for hepatitis B surface an...
Midazolam is a small molecule drug studied by Pfizer in healthy adult volunteers. It appears in a Phase 1 drug-drug interaction study alongside CP-690,550, also known as tofacitinib. The trial enrolled 25 participants and has been completed. Midazolam is not described here as a treatment for a specific disease.
Pfizer, Inc. (ticker PFE) is the developer listed for the CP-690,550 and midazolam drug-drug interaction study. The work was conducted in the United States in healthy volunteers rather than in patients with a disease indication.
The CP-690,550 and midazolam drug-drug interaction study is a Phase 1 trial. It has been completed, and it enrolled 25 healthy adult volunteers aged 18 years and older. The study was randomized and controlled, and it was not double blind.
The trial is NCT00902460, titled CP-690,550 and Midazolam Drug-Drug Interaction Study. It was a Phase 1, randomized, controlled study of 25 healthy volunteers conducted in the United States. The trial is listed as completed, and no active trials of this combination are ongoing.
In this Phase 1 study, midazolam was administered to healthy adult volunteers as part of a drug-drug interaction assessment with CP-690,550. The trial enrolled 25 participants in the United States and is completed. Midazolam is not being studied here for a disease treatment.